. Author manuscript; available in PMC: 2021 Aug 17.

Published in final edited form as: Br J Haematol. 2020 Jan 20;189(2):318–322. doi: 10.1111/bjh.16336

Table 2.

Baseline and clinical features of de novo vs. post-transplantation T- LGLL cases

Variables	de novo T-LGLL	PT T-LGLL	P-value
Total (n)	231	15
Age, median (range) in years	65 (18-89)	55 (16-65)	0.0002 ^A
≥ 60 y, n(%)	159 (69)	2 (13)	<0.0001 ^B
Gender
M/F	53/47	60/40	0.6^B
Conventional cytogenetic ^†
Abnormal, n(%)	8 (3)	2 (15)	0.07^B
LGL count, median (range) in k/μL	1.3 (0.01-970)	4.5 (0.1-12.4)	0.0005 ^A
TCR-R^†, n(%)	140 (96)	14 (100)	1^B
*STAT3*^MT^†, n(%)	87 (39)	2 (15)	0.1^B
Splenomegaly	60 (26)	5 (33)	0.5^B
Hematological features ^*
Neutropenia, n(%)	99 (43)	4 (27)	0.3^B
Anemia, n(%)	127 (55)	3 (20)	0.01 ^B
Thrombocytopenia, n(%)	80 (35)	5 (33)	1^B

^†

Some data were unable to assess

Neutropenia, absolute neutrophil count <1.5 x 10⁹/L; Anemia, hemoglobin <10 g/dL; Thrombocytopenia, platelet count <150 x 10⁹/L.

Abbreviations: T-LGLL, T-cell large granular lymphocytic leukaemia; PT T-LGLL, post-transplant T-cell large granular lymphocytic leukaemia; TCR-R, T-cell receptor gene rearrangement; STAT3^MT, STAT3 mutant; M, male; F, female; y, years; n, number.

Wilcoxon test, 2-sided

Fisher’s exact test

Significantly different parameters are in bold text.